Post-earnings recap
Reported
Wed, May 3, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics is facing challenges, as reflected in the EPS miss. However, the stock rose by 4.53%, suggesting that investors may be optimistic about the company's long-term potential despite current difficulties. The lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | -15.79% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the market conditions. They highlighted their commitment to innovation and long-term strategies.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term growth despite short-term setbacks.